Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PEL
MCID: LYM126
MIFTS: 45

Lymphoma Aids Related (PEL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lymphoma Aids Related

About this section

MalaCards integrated aliases for Lymphoma Aids Related:

Name: Lymphoma Aids Related 19
Primary Effusion Lymphoma 19 58 16 71 33
Lymphoma, Aids-Related 75 16 71
Aids-Related Lymphoma 19 75
Pel 19 58
Body Cavity-Based Lymphoma 58
Aids Related Lymphoma 19
Lymphoma Aids-Related 53

Characteristics:


Age Of Onset:

Primary Effusion Lymphoma: Adult 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32
ICD11: 33
Orphanet: 58  
Rare haematological diseases


External Ids:

MESH via Orphanet 44 D054685
ICD10 via Orphanet 32 C83.8
UMLS via Orphanet 72 C1292753
Orphanet 58 ORPHA48686
ICD11 33 697911710
UMLS 71 C0085090 C1292753
Sources

Summaries for Lymphoma Aids Related

About this section

GARD: 19 Primary effusion lymphoma (PEL) is a large B-cell lymphoma located in the body cavities, characterized by pleural, peritoneal, and pericardial fluid lymphomatous effusions and that is always associated with human herpes virus-8 (HHV-8).

MalaCards based summary: Lymphoma Aids Related, also known as primary effusion lymphoma, is related to acquired immunodeficiency syndrome and lymphoma, hodgkin, classic. An important gene associated with Lymphoma Aids Related is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Vorinostat and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone, and related phenotypes are abdominal pain and dyspnea

Orphanet: 58 Primary effusion lymphoma (PEL) is a large B-cell lymphoma located in the body cavities, characterized by pleural, peritoneal, and pericardial fluid lymphomatous effusions and that is always associated with human herpes virus-8 (HHV-8).

Wikipedia: 75 AIDS-related lymphoma describes lymphomas occurring in patients with acquired immunodeficiency syndrome... more...
Sources

Related Diseases for Lymphoma Aids Related

About this section

Diseases related to Lymphoma Aids Related via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 217)
# Related Disease Score Top Affiliating Genes
1 acquired immunodeficiency syndrome 30.8 MYC BCL6
2 lymphoma, hodgkin, classic 30.7 IL7 BCL6
3 lymphoma 30.3 TCL1A MYC BCL6
4 diffuse large b-cell lymphoma 30.1 MYC BCL6
5 reticulosarcoma 30.1 MYC BCL6
6 central nervous system lymphoma 30.0 MYC BCL6
7 plasmablastic lymphoma 30.0 MYC BCL6
8 b-cell lymphoma 29.9 TCL1A MYC BCL6
9 burkitt lymphoma 29.8 TCL1A MYC IL7 BCL6
10 peripheral t-cell lymphoma 29.6 TCL1A BCL6
11 lymphoproliferative syndrome 29.6 TCL1A BCL6
12 lymphoma, non-hodgkin, familial 29.6 TCL1A MYC IL7 BCL6
13 mature b-cell neoplasm 29.5 MYC BCL6
14 mature t-cell and nk-cell lymphoma 29.5 MYC BCL6
15 relapsed/refractory diffuse large b-cell lymphoma 29.5 MYC BCL6
16 mantle cell lymphoma 29.5 TCL1A MYC BCL6
17 lymphoma, mucosa-associated lymphoid type 29.5 MYC BCL6
18 lymphatic system disease 29.3 MYC BCL6
19 richter's syndrome 29.2 TCL1A MYC BCL6
20 follicular lymphoma 29.1 TCL1A MYC BCL6
21 leukemia, acute myeloid 29.1 MYC IL7 BCL6
22 myeloma, multiple 28.7 TCL1A MYC IL7 BCL6
23 leukemia, chronic lymphocytic 28.7 TCL1A MYC IL7 BCL6
24 human immunodeficiency virus type 1 10.8
25 pericardial effusion 10.6
26 immune deficiency disease 10.5
27 cardiac tamponade 10.4
28 liver cirrhosis 10.4
29 hepatitis c virus 10.3
30 kaposi sarcoma 10.3
31 encephalopathy, progressive, with or without lipodystrophy 10.3
32 primary central nervous system lymphoma 10.3
33 t-cell acute lymphoblastic leukemia 10.3
34 leukemia, t-cell, chronic 10.3
35 adult t-cell leukemia/lymphoma 10.2
36 reading disorder 10.2
37 hepatitis b 10.2
38 human t-cell leukemia virus type 1 10.2
39 hematologic cancer 10.1
40 cytokine deficiency 10.1
41 primary agammaglobulinemia 10.1
42 splenomegaly 10.1
43 aggressive b-cell non-hodgkin lymphoma 10.1
44 rare tumor 10.1
45 alopecia areata 10.1
46 human herpesvirus 8 10.1
47 adrenocortical carcinoma, hereditary 10.1
48 hemophagocytic lymphohistiocytosis, familial, 1 10.1
49 agammaglobulinemia, x-linked 10.1
50 deficiency anemia 10.1

Graphical network of the top 20 diseases related to Lymphoma Aids Related:



Diseases related to Lymphoma Aids Related
Sources

Symptoms & Phenotypes for Lymphoma Aids Related

About this section

Human phenotypes related to Lymphoma Aids Related:

58 30 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0002027
2 dyspnea 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0002094
3 abnormality of the peritoneum 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0002585
4 pleural effusion 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0002202
5 abdominal distention 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0003270
6 pericardial effusion 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0001698
7 b-cell lymphoma 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0012191
8 immunodeficiency 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002721

MGI Mouse Phenotypes related to Lymphoma Aids Related:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.8 BCL6 IL7 MYC
Sources

Drugs & Therapeutics for Lymphoma Aids Related

About this section

Drugs for Lymphoma Aids Related (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
2
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
3
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
4
Zidovudine Approved Phase 2 30516-87-1 35370
5
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
6
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
7
Busulfan Approved, Investigational Phase 2 55-98-1 2478
8
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
9
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
10
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
11
Allopurinol Approved Phase 2 315-30-0 2094 135401907
12
Bleomycin Approved, Investigational Phase 2 9041-93-4, 11056-06-7 5360373
13
Trimethoprim Approved, Vet_approved Phase 2 738-70-5 5578
14
Sulfamethoxazole Approved Phase 2 723-46-6 5329
15
Fluorouracil Approved Phase 2 51-21-8 3385
16
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
17
Ifosfamide Approved Phase 2 3778-73-2 3690
18
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
19
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
20
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
21
Lenograstim Approved, Investigational Phase 2 135968-09-1
22
Nivolumab Approved Phase 2 946414-94-4
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
24
Palifosfamide Investigational Phase 2 31645-39-3 100427
25 Histone Deacetylase Inhibitors Phase 1, Phase 2
26 Anti-HIV Agents Phase 2
27 Ganciclovir triphosphate Phase 2
28 Reverse Transcriptase Inhibitors Phase 2
29 Folic Acid Antagonists Phase 2
30 Vitamins Phase 2
31 Folate Phase 2
32 Vitamin B9 Phase 2
33 Trace Elements Phase 2
34 Antiprotozoal Agents Phase 2
35 Antiparasitic Agents Phase 2
36 Vitamin B Complex Phase 2
37 Antimalarials Phase 2
38 Calcium, Dietary Phase 2
39 Antidotes Phase 2
40 Trimethoprim, Sulfamethoxazole Drug Combination Phase 2
41 Cytochrome P-450 Enzyme Inhibitors Phase 2
42 Micronutrients Phase 2
43 Interleukin-12 Phase 2
44 Anti-Retroviral Agents Phase 2
45 Immunoglobulin G Phase 2
46 Immune Checkpoint Inhibitors Phase 2
47
Calcium Nutraceutical Phase 2 7440-70-2 271
48
Picropodophyllin Approved, Investigational Phase 1 518-28-5, 477-47-4 10607 72435
49
Posaconazole Approved, Investigational, Vet_approved Phase 1 171228-49-2 147912
50
Cortisone Experimental Phase 1 53-06-5 222786

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma Completed NCT01193842 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate;Vorinostat
2 Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir Completed NCT00217503 Phase 2 bortezomib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ganciclovir;valganciclovir;zidovudine
3 Feasibility Study of CO-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma Completed NCT00799136 Phase 2 R-EPOCH and cART
4 Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II Completed NCT00002571 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;prednisone;trimethoprim-sulfamethoxazole;vincristine sulfate;Intrathecal cytarabine
5 Pilot Study in AIDS-Related Lymphomas Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
6 First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at "High Risk", Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation Completed NCT01045889 Phase 2
7 Pilot Study of the Safety and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation for Patients With Relapsed AIDS-Related Lymphoma Completed NCT00005824 Phase 2 busulfan;cyclophosphamide
8 EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Completed NCT00001563 Phase 2 EPOCH
9 Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa Completed NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;procarbazine hydrochloride
10 Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma Recruiting NCT02911142 Phase 1, Phase 2 Lenalidomide;Rituximab;Prednisone;Etopside;Doxorubicin;Vincristine;Cyclophosphamide
11 Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue - Auto -RESIST. BMTCTN1903 Recruiting NCT04975698 Phase 2
12 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Active, not recruiting NCT03038672 Phase 2 Varlilumab
13 Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas Active, not recruiting NCT00006436 Phase 2 EPOCH
14 High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT Terminated NCT00858793 Phase 1, Phase 2
15 Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab + CHOP Regimen in Patients With HIV Related Non-Hodgkin's Lymphomas. ANRS 085 Rituximab Terminated NCT00126243 Phase 2 rituximab;CHOP
16 Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
17 Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD) Withdrawn NCT00024128 Phase 2 cyclophosphamide;cyclosporine
18 Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Withdrawn NCT00310128 Phase 2 cisplatin;cytarabine;etoposide;methylprednisolone;rituximab;yttrium Y 90 ibritumomab tiuxetan
19 A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies Recruiting NCT05544019 Phase 1 SGR-1505
20 To Evaluate the Safety, Efficacy, Pharmacokinetics of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia Recruiting NCT05340829 Phase 1
21 Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas Recruiting NCT03220022 Phase 1 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ibrutinib;Prednisone;Vincristine Sulfate
22 Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs Active, not recruiting NCT01961063 Phase 1 busulfan
23 Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs Active, not recruiting NCT02337985 Phase 1 Prednisone;Etoposide;Doxorubicin Hydrochloride;Vincristine Sulfate;Cyclophosphamide
24 Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas Not yet recruiting NCT05389423 Phase 1 Vincristine;Prednisone;Doxorubicin;Etoposide;Pomalidomide;Cyclophosphamide;Rituximab
25 Autologous Transplantation and Stem Cell-Based Gene Therapy With LVsh5/C46 (CAL-1), a Dual Anti-HIV Lentiviral Vector, for the Treatment of HIV-Associated Lymphoma Withdrawn NCT02378922 Phase 1
26 A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma Completed NCT02652715
27 Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy Completed NCT03690895
28 A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines Completed NCT00001571
29 The Evaluation of Focal Contrast-Enhancing Brain Lesions in HIV-Infected Patients Completed NCT00226304
30 Oncogenic Viral Pathogenesis and Cancer Risk Factors Among Patients With the Acquired Immunodeficiency Syndrome: A Prospective Cohort Study Completed NCT00001120
31 French Cohort of HIV Associated Lymphomas Completed NCT01164436
32 Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer Recruiting NCT00006518
33 Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group Recruiting NCT05231135
34 Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis Active, not recruiting NCT04742387
35 Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AIDS Malignancy Consortium A Trial of the AIDS Malignancy Consortium (AMC) Not yet recruiting NCT05510908
36 Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies Temporarily not available NCT02822495
37 Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma Terminated NCT02823327
38 AUTOLOGOUS TRANSPLANTATION AND STEM CELL BASED-GENE THERAPY FOR THE TREATMENT OF HIV-ASSOCIATED LYMPHOMA Withdrawn NCT01769911 carmustine;cytarabine;melphalan;etoposide;O6-benzylguanine

Search NIH Clinical Center for Lymphoma Aids Related

Sources

Genetic Tests for Lymphoma Aids Related

About this section
Sources

Anatomical Context for Lymphoma Aids Related

About this section

Organs/tissues related to Lymphoma Aids Related:

MalaCards : Bone Marrow, T Cells, Bone, Brain, Endothelial, B Cells, Lymph Node
Sources

Publications for Lymphoma Aids Related

About this section

Articles related to Lymphoma Aids Related:

(show top 50) (show all 1687)
# Title Authors PMID Year
1
Simian AIDS-related lymphoma growth in severe combined immunodeficiency mice is independent of karyotypic abnormalities or Bcl-6 mutations. 53 62
11897040 2002
2
BCL-6 in aids-related lymphomas: pathogenetic and histogenetic implications. 53 62
9720713 1998
3
Involvement of the bcl-6 gene in AIDS-related lymphomas. 53 62
9209652 1997
4
HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review. 62
35916333 2022
5
Primary Leptomeningeal Lymphoma: Clinicopathologic Features of 2 Rare Phenotypes. 62
36102830 2022
6
Mitochondrial protein, TBRG4, modulates KSHV and EBV reactivation from latency. 62
36417478 2022
7
Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases. 62
35848586 2022
8
Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1. 62
36416587 2022
9
Kaposi's Sarcoma-associated Herpesvirus Replication and Transcription Activator Protein Activates CD274/PD-L1 Gene Promoter. 62
36411531 2022
10
Nm23-H1 induces apoptosis in primary effusion lymphoma cells via inhibition of NF-κB signaling through interaction with oncogenic latent protein vFLIP K13 of Kaposi's sarcoma-associated herpes virus. 62
35964258 2022
11
Host-Level Susceptibility and IRF1 Expression Influence the Ability of IFN-γ to Inhibit KSHV Infection in B Lymphocytes. 62
36298850 2022
12
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. 62
35562413 2022
13
Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells. 62
35262781 2022
14
Human Herpesvirus 8 in Australia: DNAemia and Cumulative Exposure in Blood Donors. 62
36298740 2022
15
Primary Effusion Lymphoma-like ATL Developing During Hemodialysis. 62
36261387 2022
16
The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines. 62
36094314 2022
17
Druggable host gene dependencies in primary effusion lymphoma. 62
36182745 2022
18
High expression of HIV-1 matrix protein p17 in both lymphoma and lymph node tissues of AIDS patients. 62
35939971 2022
19
Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma. 62
36066839 2022
20
DExD/H Box Helicases DDX24 and DDX49 Inhibit Reactivation of Kaposi's Sarcoma Associated Herpesvirus by Interacting with Viral mRNAs. 62
36298642 2022
21
HHV-8 associated lymphoma. 62
35838208 2022
22
Biomolecular Fluorescence Complementation Profiling and Artificial Intelligence Structure Prediction of the Kaposi's Sarcoma-Associated Herpesvirus ORF18 and ORF30 Interaction. 62
36077046 2022
23
Adaptive immune responses to Kaposi's sarcoma-associated herpesvirus. 62
35810680 2022
24
Concomitant Inhibition of IRE1α/XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas. 62
36012375 2022
25
Immunotherapy for KSHV-associated diseases. 62
35803203 2022
26
SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma. 62
35914074 2022
27
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. 62
35472248 2022
28
Kaposi sarcoma (KS) with primary effusion lymphoma in HIV infected MSM (men having sex with men) co-infected with pulmonary tuberculosis and syphilis: a case report from India. 62
35842670 2022
29
Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study. 62
35110006 2022
30
STAT and Janus kinase targeting by human herpesvirus 8 interferon regulatory factor in the suppression of type-I interferon signaling. 62
35776779 2022
31
Molecular and immune interactions between β- and γ-herpesviruses in the immunocompromised host. 62
35060655 2022
32
A case report-application of pericardial effusion cytology and next-generation sequencing technology: quick and secure diagnosis of primary effusion lymphoma. 62
35821972 2022
33
Primary Effusion Lymphoma Presenting As Parapneumonic Pleural Effusion. 62
35847166 2022
34
Flow Cytometric Findings in Primary Effusion Lymphoma: A Report of Two Cases. 62
35785002 2022
35
Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF). 62
35743211 2022
36
KSHV RTA Induces Degradation of the Host Transcription Repressor ID2 To Promote the Viral Lytic Cycle. 62
35604218 2022
37
Hypoalbuminemia predicts inferior outcome in patients with AIDS-related lymphoma. 62
35717275 2022
38
Mechanistic insights into the activation of the IKK kinase complex by the Kaposi's sarcoma herpes virus oncoprotein vFLIP. 62
35525271 2022
39
Thymus capitatus flavonoids inhibit infection of Kaposi's sarcoma-associated herpesvirus. 62
35384415 2022
40
Immune checkpoints in T cells during oncogenic γ-herpesvirus infections. 62
35524342 2022
41
Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. 62
34545416 2022
42
CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules. 62
35562811 2022
43
[HHV-8 Related immunological and hematological diseases]. 62
34895767 2022
44
Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest. 62
35316715 2022
45
Lymphoproliferative Neoplasms With Plasmablastic Morphology. 62
34559873 2022
46
A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. 62
34560683 2022
47
A pyridinium‑type fullerene derivative suppresses primary effusion lymphoma cell viability via the downregulation of the Wnt signaling pathway through the destabilization of β‑catenin. 62
35014678 2022
48
Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells. 62
35453482 2022
49
Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV. 62
35328266 2022
50
Synchronous visceral Kaposi sarcoma and extracavitary primary effusion lymphoma in a patient with AIDS. 62
35351773 2022
Sources

Variations for Lymphoma Aids Related

About this section

Copy number variations for Lymphoma Aids Related from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25103 1 184000000 197500000 Gain primary effusion lymphomas
2 189792 4 78400000 172200000 Gain primary effusion lymphomas
3 239813 8 41800000 84900000 Gain primary effusion lymphomas
4 262574 X 37500000 98200000 Gain primary effusion lymphomas
Sources

Expression for Lymphoma Aids Related

About this section
Search GEO for disease gene expression data for Lymphoma Aids Related.
Sources

Pathways for Lymphoma Aids Related

About this section

Pathways related to Lymphoma Aids Related according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 12.62 MYC IL7 BCL6
2
PI3K-Akt signaling pathway 74
Show member pathways
 11.61 TCL1A MYC IL7
3
Vitamin D receptor pathway 74
11.59 MYC BCL6
4
Interleukin-4 and Interleukin-13 signaling 66
11.29 MYC BCL6
5
DNA damage response (only ATM dependent) 74
11.16 MYC BCL6
6
Notch Signaling Pathways 65
10.96 MYC BCL6
Sources

GO Terms for Lymphoma Aids Related

About this section

Biological processes related to Lymphoma Aids Related according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 9.73 TCL1A MYC IL7
2 B cell proliferation GO:0042100 9.46 IL7 BCL6
3 positive regulation of B cell proliferation GO:0030890 9.26 IL7 BCL6
4 negative regulation of apoptotic process GO:0043066 9.17 TCL1A MYC IL7 BCL6
Sources

Sources for Lymphoma Aids Related

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....